-
Plenary Session I: Thursday, October 18, 2018
"Improving Outcomes of Infections in the Age of CFTR Modulators"
Speaker: Lisa Saiman, M.D., M.P.H.
In this session, Dr. Lisa Saiman will address the challenges
of infections in people with CF and discuss why infections remain a major focus
of the CF community, even in the era of effective CFTR modulators. She will
provide an overview of CF infections, describe ongoing studies to increase our
understanding of CF microorganisms and their optimal treatment, and discuss
current strategies to develop new anti-infective agents to treat even the most
difficult infections.
-
Plenary Session II: Friday, October 19, 2018
"Anti-inflammatories & Mucociliary Clearance Therapies in the Age of CFTR Modulators"
Speaker: Felix Ratjen, M.D., Ph.D.
This plenary will review the effect of CFTR dysfunction and
CFTR restoration on both inflammation and mucociliary clearance in individuals
with CF. Current and future therapeutic strategies to address inflammation and
mucociliary clearance will be discussed, as well as how these strategies have
potential to benefit both those patients using CFTR modulators and those not
eligible for modulators.
-
Plenary Session I: Thursday, November 2, 2017
"Matching Medicines With Mutations"
Speakers: Michael P. Boyle, M.D., FCCP and Philip J. Thomas, Ph.D.
Increasing
numbers of people with CF now benefit from disease-altering small molecule
therapies that target the basic defect in CFTR. Use of these therapies
has been extended recently using a combination of in vitro laboratory
experiments to identify responsive mutations, and clinical trials to determine
effect on clinical outcomes. This plenary will summarize how recent advances
may allow in the near future over 90% of individuals with CF to benefit from
therapies that target the basic defect in CFTR, including even those with the
rarest disease causing mutations.
-
Plenary Session II: Friday, November 3, 2017
"Lung Transplantation: Challenges & Opportunities for Advanced CF Lung Disease"
Speakers: Joseph Pilewski, M.D.
Plenary 2 will review the
progression of CF lung disease and the option of lung transplant to treat
advanced disease. The presentation will highlight the challenges associated
with each phase of the transplant journey, including the referral to a transplant
center, waiting for a transplant, undergoing the transplant procedure, and the
care requirements and life after transplant.
-
Plenary Session II: Friday, October 28, 2016
"Clinical Research: A Worldwide CF Community Effort"
Speakers: Christiane De Boeck, M.D., Ph.D. and Patrick Flume, M.D.
The cystic fibrosis clinical trial pipeline is at present very busy -- and this is great news. This session explains how worldwide collaboration and streamlining can optimize the efficiency in the clinical trial arena.
-
Plenary Session I: Thursday, October 8, 2015
"Personalized Medicine"
Speaker: John Paul Clancy, M.D.
This session discusses the concept of personalized medicine in cystic fibrosis, including how therapies are currently personalized and how new medications and tools will allow us to personalize therapy in a precise way.